Edition:
United States

Forward Pharma A/S (FWP.OQ)

FWP.OQ on NASDAQ Stock Exchange Global Select Market

1.20USD
2:19pm EDT
Change (% chg)

$0.02 (+1.69%)
Prev Close
$1.18
Open
$1.18
Day's High
$1.20
Day's Low
$1.18
Volume
568
Avg. Vol
5,083
52-wk High
$4.42
52-wk Low
$0.71

About

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company's clinical candidate, FP187, is under development... (more)
No analyst recommendations are available for .

Overall

Beta: 2.71
Market Cap(Mil.): $56.09
Shares Outstanding(Mil.): 23.77
Dividend: 23.12
Yield (%): --

Financials

  FWP.OQ Industry Sector
P/E (TTM): -- 109.48 62.40
EPS (TTM): -0.18 -- --
ROI: -10.15 7.96 11.78
ROE: -10.15 8.11 12.61

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

Oct 24 2018

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

Oct 24 A U.S. appeals court on Wednesday upheld a ruling that patents owned by Biogen Inc covering its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

Oct 24 2018

Earnings vs. Estimates